Stock VIR VIR BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Vir Biotechnology, Inc.

Equities

VIR

US92764N1028

Real-time Estimate Cboe BZX
Other stock markets
 02:01:08 2024-06-10 pm EDT 		5-day change 1st Jan Change
10.96 USD -2.40% Intraday chart for Vir Biotechnology, Inc. +2.09% +7.87%
Jun. 06 Morgan Stanley Adjusts Price Target on Vir Biotechnology to $15 From $12, Maintains Equal-Weight Rating MT
Jun. 05 Sector Update: Health Care Stocks Steady Premarket Wednesday MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vir Biotechnology - Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus
AQ
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
BU
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BU
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
BU
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
BU
Multiple Abstracts highlighting Vir Biotechnology's Latest Hepatitis Delta and B Data Accepted for Presentation at the EASL Congress 2024
AQ
Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
BU
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
BU
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
BU
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
BU
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
BU
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
BU
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
AQ
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
BU
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
AQ
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
BU
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer
BU
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
BU
Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VIR Stock
  4. News Vir Biotechnology, Inc.
  5. Press Releases